Commentary

Video

Earlier CAR T Use in Multiple Myeloma: Game Changer or Boutique Medicine?

Author(s):

Krina K. Patel, MD, MSc

Krina K. Patel, MD, MSc, discusses her thoughts on moving CAR T-cell therapy up in the lines of treatment for patients with multiple myeloma.

Krina K. Patel, MD, MSc, discusses her thoughts on moving CAR T-cell therapy up in the lines of treatment for patients with multiple myeloma.

Related Videos
C. Ola Landgren, MD, PhD
David Samuel Dicapua Siegel, MD
Alfred L. Garfall, MD, MS
Noa Biran, MD
Noa Biran, MD
Alfred L. Garfall, MD, MS
Amrita Krishnan, MD, City of Hope
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)
Noa Biran, MD
Mohamad Mohty, MD, PhD
Related Content
Nausheen Ahmed, MD, MBBS
July 24th 2024

Reduced Incidence of ICANS and CRS After 2 Weeks Post-CAR T Supports Shortened Monitoring Period in DLBCL

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

C. Ola Landgren, MD, PhD, of Sylvester Comprehensive Cancer Center
July 19th 2024

Four-Drug Regimens Escalate the SOC for Newly Diagnosed Multiple Myeloma

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Francisco Hernandez-Ilizaliturri, MD, of Roswell Park
July 17th 2024

Sequencing of Bispecific Antibodies vs CAR T-Cell Therapies is Dependent on Several Factors in DLBCL, Multiple Myeloma

Francisco Hernandez-Ilizaliturri, MD
July 15th 2024

CAR T-Cell Therapy Selection in Follicular Lymphoma Requires Careful Consideration